Results 101 to 110 of about 4,644,669 (318)

Cost effectiveness and cost utility of the noncoding blood glucose meter CONTOUR® TS

open access: yesDiabetes, Metabolic Syndrome and Obesity, 2011
Przemyslaw Holko, Pawal KawalecHTA Centre, Kraków, PolandAims: This study assessed the cost efficacy and cost utility of the automatic blood glucose meter CONTOUR® TS from the public payer (National Health Fund [NHF]) and payer ...
Przemyslaw Holko, Pawal Kawalec
doaj  

Efficiency of hospitals in COVID-19 era: a case study of an affected country

open access: yesCost Effectiveness and Resource Allocation
Background The COVID-19 pandemic has affected all aspects of human life and society and has damaged the global economy. Health systems and hospitals were not exempted from this situation.
Anita Hamdollahzadeh   +2 more
doaj   +1 more source

Cost-effectiveness of rotavirus vaccination in peru.

open access: yes, 2009
BACKGROUND: There are plans to introduce the oral rotavirus vaccine Rotarix (GlaxoSmithKline), 1 of 2 recently developed vaccines against rotavirus, in Peru.
Walker, Damian G   +6 more
core   +1 more source

A note on the estimation of confidence intervals for cost-effectiveness when costs and effects are censored [PDF]

open access: yes, 2002
<i>Background</i>. The relation between methodological advances in estimation of confidence intervals (CIs) for incremental cost-effectiveness ratios (ICER) and estimation of cost effectiveness in the presence of censoring has not been ...
Briggs, AH   +5 more
core   +1 more source

One size does not fit all: An in vitro evaluation of the effects of bezafibrate and medroxyprogesterone acetate on human SH‐SY5Y and U‐87 MG cancer cells

open access: yesFEBS Open Bio, EarlyView.
Drugs previously repurposed to target blood cancers reduced neuroblastoma and glioblastoma cell growth and viability. However, their levels of anticancer activity were different and their clinical application may be problematic due to side effects at effective doses.
Abhishek Kharawatkar   +4 more
wiley   +1 more source

Versatile vector tools for efficient protein screening across multiple expression systems

open access: yesFEBS Open Bio, EarlyView.
A unified vector toolkit enables rapid protein expression screening across E. coli, insect, and mammalian cells. A single primer pair amplifies the target gene, which is inserted into any vector via a standardized interface. This streamlined workflow eliminates repeated cloning steps, accelerating the identification of optimal expression conditions for
Zhimin Zhu   +5 more
wiley   +1 more source

Emerging insights into CC and CXC chemokines and their receptors in Mycobacterium tuberculosis infection

open access: yesFEBS Open Bio, EarlyView.
The dual roles of CC and CXC chemokines in distinguishing active, latent, and subclinical tuberculosis were reviewed, along with an evaluation of their potential as diagnostic biomarkers and therapeutic targets to advance precision medicine in tuberculosis management. The graphical abstract was generated with AI assistance (Gemini 3.0).
Xuying Yin, Dangsheng Xiao, Jiezuan Yang
wiley   +1 more source

Costs and cost-effectiveness of delivering intermittent preventive treatment through schools in western Kenya. [PDF]

open access: yes, 2008
BACKGROUND: Awareness of the potential impact of malaria among school-age children has stimulated investigation into malaria interventions that can be delivered through schools. However, little evidence is available on the costs and cost-effectiveness of
Matthew CH Jukes   +24 more
core   +1 more source

Directed evolution of enzymes at the crossroads of tradition and innovation

open access: yesFEBS Open Bio, EarlyView.
An iterative cycle of data‐driven enzyme optimization comprising four stages: genetic diversification of a template enzyme, expression of protein variants, high‐throughput evaluation, and machine‐learning‐guided redesign of the next variant library.
Maria Tomkova   +2 more
wiley   +1 more source

Cost-effectiveness of combination fluticasone propionate&ndash;salmeterol 250/50 &mu;g versus salmeterol in severe COPD patients

open access: yesInternational Journal of COPD, 2010
Anand A Dalal1, Meaghan St Charles2, Hans V Petersen2, Melissa H Roberts2, Christopher M Blanchette2, Kathy Manavi-Zieverink31US Health Outcomes, GlaxoSmithKline, Research Triangle Park, NC, 2Division of Clinical and Outcomes Research, Lovelace ...
An   +4 more
doaj  

Home - About - Disclaimer - Privacy